- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05837845
MDMA-assisted Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder
A Randomized Trial to Compare MDMA-assisted Therapy (MDMA-AT) Versus Cognitive Processing Therapy (CPT), a VA Standard-of-care Psychotherapy for PTSD, for the Treatment of Severe Posttraumatic Stress Disorder
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Posttraumatic stress disorder (PTSD) is a serious debilitating disorder that negatively impacts a person's daily life, and can result in diminished cognitive and psychosocial functioning, fractured relationships, inability to maintain employment, substance use disorders, high-cost healthcare utilization, increased depression, and suicide risk. People who suffer from PTSD relive their traumatic experience(s) through nightmares and flashbacks, have difficulty sleeping, and feel detached or estranged. Symptoms can be severe and long lasting.
Many available PTSD treatments, including medications and therapy, effectively treat only a fraction of people who try them. This indicates a need to assess treatments targeting durable remission of PTSD. An extensive list of medications, namely antipsychotics, anxiolytics, antidepressants, and sleep aids, are frequently prescribed off-label but are minimally effective in reducing PTSD symptoms.
MDMA-assisted therapy is a novel treatment package that combines psychotherapeutic techniques with the administration of MDMA as a pharmacological adjunct intended to enhance certain aspects of therapy. The subjective effects of MDMA create a productive psychological state that enhances the therapeutic process. The Multidisciplinary Association for Psychedelic Studies (MAPS) is a non-profit research and educational organization working as a clinical trial sponsor to obtain approval for the prescription use of 3,4-methylenedioxymethamphetamine (MDMA) as an adjunct to therapy in patients with treatment-resistant PTSD. Data from a series of Phase 2 and Phase 3 studies of MDMA-assisted therapy conducted by MAPS provide preliminary evidence that chronic PTSD, independent of cause, is treatable with up to three sessions of MDMA-assisted therapy and associated non-drug preparatory and integrative therapy sessions.
Cognitive Processing Therapy (CPT) is a cognitively-oriented approach to treating PTSD developed in the late 1980's by Dr. Patricia Resick. Significant research on CPT has been conducted in the VA system nationally. Across a number of studies, a meta-analysis found the number of subjects that no longer meet PTSD criteria after receiving a full course of CPT ranged from 30% to 97%, and 51% of subjects receiving CPT achieved loss of diagnosis compared to waitlist, self-help booklets, and treatment as usual control groups. There are various task forces and active efforts to deploy CPT more broadly in the VA. The comparison of CPT and MDMA-assisted therapy for treatment of PTSD is very timely given the tremendous need to treat PTSD throughout the VA system, making this comparison all the more pertinent.
PTSD carries a high public burden, both economically and socially, by increased healthcare utilization, use of social services, lost wages, and disability payments. Given the chronicity of PTSD, low treatment compliance evidenced by high dropouts, and limited recovery with current medications contributing to serious outcomes, PTSD patients exhibit an unmet medical need. Currently, the VA serves approximately nine million Veterans and the conservative estimate of those with PTSD is 25%, or over two million Veterans. The potential importance and benefits of this novel treatment to Veterans, doctors, researchers, and the VA system cannot be underestimated. The clinical effectiveness, implementation evaluation, and economic assessment conducted in this study will provide critical information and understanding of the feasibility of utilization in the VA system.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Sara Ellis
- Phone Number: 650-849-0161
- Email: exploratorytherapeuticslab@stanford.edu
Study Locations
-
-
California
-
Palo Alto, California, United States, 94304
- VA Palo Alto Health Care System / Stanford University
-
Contact:
- Sara Ellis
- Phone Number: 650-849-0161
- Email: seellis3@stanford.edu
-
Principal Investigator:
- Trisha Suppes, MD, PhD
-
Sub-Investigator:
- Shannon Wiltsey Stirman, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Participants are eligible to be included in the study only if all of the following criteria apply:
- Are at least 18 years at the time of signing the informed consent.
- Are a U.S Military Veteran
- Are receiving services from VA Palo Alto Healthcare System, VA San Francisco Healthcare System, or VA NorCal Healthcare System
- Are fluent in speaking and reading in English
- Agree to have study visits audio and/or video recorded
- Able to identify appropriate support person(s) to stay with the participant on the evenings of the Experimental Sessions.
- Meet DSM-5 criteria for current severe PTSD with a symptom duration of at least 6 months.
- Have severe PTSD symptoms in the last month.
- Body weight of at least 48 kilograms (kg).
- Is not pregnant, planning to get pregnant, or breastfeeding
- Capable of giving signed informed consent
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
- Have a history of any medical condition that could make receiving a sympathomimetic drug harmful
- Have current unstable medical illness
- Have cardiac conditions, including uncontrolled hypertension, prolonged QTc interval, and other cardiac conditions
- Have received Electroconvulsive Therapy (ECT), ketamine-assisted therapy, or used ketamine within 12 weeks of enrollment
- Have an active alcohol or substance use disorder
- Have current serious suicide risk
- Unable or unwilling to stop or safely taper off prohibited medications
- Have used Ecstasy more than 10 times within the last 10 years
- Currently enrolled in any clinical study
- Have a history of or current psychotic disorders, bipolar disorder type I, or severe personality disorders
- Lack social support, or lack a stable living situation
- Previous participation in a MAPS-sponsored MDMA clinical trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MDMA-assisted therapy (MDMA-AT)
This arm consists of three, 90-minute, non-drug Preparatory Sessions and a ~12-week Treatment Period comprised of three Experimental Sessions with MDMA (~ 8 hours), each followed by three 90-minute, non-drug Integration Sessions.
Participants will receive 60mg MDMA HCl for first Experimental Session and 60mg or 120mg MDMA HCl for following Experimental Sessions.
During each Experimental Session, participants will have the option of receiving a supplemental dose of 40mg or 60mg MDMA HCl 1.5-2 hours after the initial dose.
Participants will have the option to crossover to the CPT arm 6 months after all study visits are completed.
|
Participants will receive a flexible divided-dose of MDMA HCl plus therapy at three Experimental Sessions, as well as non-drug Preparatory and Integration Sessions
Participants assigned to MDMA and d-amphetamine will undergo a therapeutic approach, which is detailed in the MDMA-Assisted Therapy Treatment Manual and administered by MAPS-trained therapists.
In brief, this therapy is guided by the subject's own recollections of traumatic events.
The subject and two therapists provide a comfortable and supportive environment and allow the subject to guide the discussion.
Subjects are encouraged to experience and express fear, anger, and grief with less likelihood of feeling overwhelmed by these emotions.
MDMA seems to engender internal awareness that even painful feelings that arise are an important part of the therapeutic process.
In addition, feelings of empathy, love, and deep appreciation often emerge, along with a clearer perspective of the trauma as a past event, a more accurate perspective about its significance, and a heightened awareness of the support and safety that exists in the present.
|
Experimental: Cognitive processing therapy
This arm consists of one, 60-minute, introductory meeting with the therapist followed by a ~12-week Treatment Period comprised of 12 1-hour CPT sessions with three optional additional sessions, each approximately one week apart.
Participants will have the option to crossover to the MDMA-AT arm 6 months after all study visits are completed.
|
Participants will receive 12-16 sessions of Cognitive Processing Therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Clinician Administered PTSD Scale (CAPS-5) Total Severity Score
Time Frame: From Baseline to approximately 4 months post-baseline
|
The Primary Outcome measure will be the change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Severity Score from Baseline to 4 months post-baseline assessed by a blinded study staff rater. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms. |
From Baseline to approximately 4 months post-baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Quality of Life Enjoyment and Satisfaction Questionnaire
Time Frame: From Baseline to approximately 4 months post-baseline
|
The secondary outcome measure will be the change in the8.6.2.2 Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q-SF), assessed by a blinded study staff rater. The Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) is a self-report measure designed to enable investigators to easily obtain sensitive measures of the degree of enjoyment and satisfaction experienced by subjects in various areas of daily functioning. The summary scores were found to be reliable and valid measures of these dimensions in a group of depressed outpatients. The Q-LES-Q measures were related to, but not redundant with, measures of overall severity of illness or severity of depression within this sample. These findings suggest that the Q-LES-Q measures may be sensitive to important differences among depressed patients that are not detected by the measures usually employed. |
From Baseline to approximately 4 months post-baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Trisha Suppes, MD, PhD, VA Palo Alto Healthcare System / Stanford University
- Principal Investigator: Shannon Wiltsey Stirman, PhD, VA Palo Alto Healthcare System / Stanford University
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Trauma and Stressor Related Disorders
- Stress Disorders, Traumatic
- Stress Disorders, Post-Traumatic
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Hallucinogens
- Adrenergic Uptake Inhibitors
- N-Methyl-3,4-methylenedioxyamphetamine
Other Study ID Numbers
- IVAPT1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on PTSD
-
University of PittsburghCompletedPTSD | Non PTSDUnited States
-
Imperial College Healthcare NHS TrustImperial College LondonRecruiting
-
VA Office of Research and DevelopmentUniversity of California, San DiegoRecruiting
-
University of Wisconsin, MadisonNational Institute of Mental Health (NIMH)Active, not recruiting
-
Oregon Health and Science UniversityEnrolling by invitation
-
VA Office of Research and DevelopmentCompleted
-
VA Office of Research and DevelopmentPortland VA Medical CenterActive, not recruiting
-
VA Office of Research and DevelopmentSan Diego Veterans Healthcare SystemCompleted
-
Creighton UniversityCompleted
-
VA Eastern KansasTerminated
Clinical Trials on MDMA
-
Willa HallNot yet recruitingAdjustment Disorders | Post-Traumatic Stress Disorder
-
RemedyMultidisciplinary Association for Psychedelic StudiesActive, not recruitingPost Traumatic Stress DisorderCanada
-
University of ChicagoCompletedHealthy | Autism Spectrum DisorderUnited States
-
University of ChicagoCompleted
-
Spaulding Rehabilitation HospitalMultidisciplinary Association for Psychedelic StudiesNot yet recruiting
-
Lykos TherapeuticsCompletedPosttraumatic Stress Disorder (PTSD)Israel
-
University of California, Los AngelesNot yet recruitingPsychotherapy | Adolescents | PTSD, Post Traumatic Stress DisorderUnited States
-
Lykos TherapeuticsCompletedPosttraumatic Stress DisorderUnited States
-
University of Southern CaliforniaMultidisciplinary Association for Psychedelic StudiesActive, not recruiting
-
Dr. Leslie MorlandSan Diego Veterans Healthcare System; Healing Breakthrough; Lykos TherapeuticsRecruitingPTSD | Relational ProblemsUnited States